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Abstract 
Aim: Muscular dystrophy (MD) is a progressive disease with predominantly muscular symptoms. Myotonic dystrophy 
type II (MD2) and facioscapulohumeral muscular dystrophy type 1 (FSHD1) are gaining an increasing awareness, but 
data on cardiac involvement are conflicting. The aim of this study was to determine a progression of cardiac remod‑
eling in both entities by applying cardiovascular magnetic resonance (CMR) and evaluate its potential relation to 
arrhythmias as well as to conduction abnormalities.
Methods and results: 83 MD2 and FSHD1 patients were followed. The participation was 87% in MD2 and 80% 
in FSHD1. 1.5 T CMR was performed to assess functional parameters as well as myocardial tissue characterization 
applying T1 and T2 mapping, fat/water‑separated imaging and late gadolinium enhancement. Focal fibrosis was 
detected in 23% of MD2) and 33% of FSHD1 subjects and fat infiltration in 32% of MD2 and 28% of FSHD1 subjects, 
respectively. The incidence of all focal findings was higher at follow‑up. T2 decreased, whereas native T1 remained 
stable. Global extracellular volume fraction (ECV) decreased similarly to the fibrosis volume while the total cell volume 
remained unchanged. All patients with focal fibrosis showed a significant increase in left ventricular (LV) and right 
ventricular (RV) volumes. An increase of arrhythmic events was observed. All patients with ventricular arrhythmias 
had focal myocardial changes and an increased volume of both ventricles (LV end‑diastolic volume (EDV) p = 0.003, 
RVEDV p = 0.031). Patients with supraventricular tachycardias had a significantly higher left atrial volume (p = 0.047).
Conclusion: We observed a remarkably fast and progressive decline of cardiac morphology and function as well 
as a progression of rhythm disturbances, even in asymptomatic patients with a potential association between an 
increase in arrhythmias and progression of myocardial tissue damage, such as focal fibrosis and fat infiltration, exists. 
These results suggest that MD2 and FSHD1 patients should be carefully followed‑up to identify early development of 
remodeling and potential risks for the development of further cardiac events even in the absence of symptoms.
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Introduction
Muscular dystrophy (MD) is a group of genetic and pro-
gressive diseases with primary symptoms of skeletal 
muscle pain and weakness. In some MD, such as Duch-
enne muscular dystrophy (DMD) and Becker muscular 
dystrophy (BMD), cardiac involvement is well known. 
Myocardial fibrosis detected by cardiovascular mag-
netic resonance (CMR) enables the prediction of cardiac 
events in DMD/BMD patients independently when com-
pared with reduced left ventricular (LV) ejection fraction 
(LVEF). Interestingly, in patients with preserved LVEF, 
there is added value of focal fibrosis [1–3]. Focal fibrosis 
may occur in up to 90% of these patients, leading to heart 
failure and sudden cardiac death (SCD) in some cases [4].
Myotonic dystrophy type II (MD2) and facioscapulo-
humeral muscular dystrophy type 1 (FSHD1) have gained 
an increasing awareness during the last years. There is a 
suspicion that MD2 as well as FSHD1 could be under-
diagnosed due to frequently mild symptoms and slower 
progression in females. Late onset and a slower progres-
sion seem to lead to a rate of 20% misdiagnosed patients 
[5]. MD2 and FSHD1 are mainly recognized as muscular 
diseases with rare cardiac involvement.
MD2 is an autosomal dominant inherited multi-
systemic muscle disease. The mutation frequency 
constitutes 1:1830 [6]. Patients often notice the first 
symptoms quite late, at the age of 37 ± 15  years [7], 
suffering from muscle weakness, myotonia and muscle 
pain.
FSHD1 is an autosomal dominant disorder and the 
third most common inherited muscle disease with an 
incidence of 1: 8.000–1: 20.000 [8]. Diagnosis of FSHD1 
is often suspected in patients with presence of progres-
sive asymmetric weakness of the face and shoulder 
muscles. However, 10–25% of patients are wheelchair-
dependent [9].
Arrhythmias in both patient groups are known but its 
relation to myocardial injury as well as evidence for pro-
gression of myocardial changes still remains unknown. 
Trevisan et  al. reported arrhythmic events in 12% of 
FSHD-patients [10], whereas in MD2 different forms of 
arrhythmias were reported in 17% to 36% of patients [11].
In our pilot studies, we were able to identify myocar-
dial injury, like fat infiltration and focal fibrosis, in over 
26% of MD2 and FSHD1 patients with preserved LVEF 
[12, 13].
Trial registration ISRCTN, ID ISRCTN16491505. Registered 29 November 2017 – Retrospectively registered, http:// www. 
isrctn. com/ ISRCT N1649 1505
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Up to 90 DCM Sinus tachycardia, Ventricular tachy‑
cardias
 +  +  +  + 
Becker muscular dystrophy 60–70 DCM AV nodal and bundle branch blocks  +  +  + No data
Emery‑Dreifuss muscular dystrophy 50–90 DCM, HCM, LVNC,
biatrial dilation
Bradycardias (AV blocks), Tachycardias 
(SVTs)




Limb girdle muscular dystrophy 25–90 DCM, HCM SVTs, Ventricular tachycardia  +  +  + 
Myofibrillar myopathy 40–60 DCM, HCM, LVNC Complete AV Block no data No data
Facioscapulohumeral muscular 
dystrophy
5–25 DCM (rare) RBBB, SVTs  + / +  +  + 
Myotonic dystrophy type 1 60–80 DCM, HCM AV Blocks, RBBB/LBBB QTc/QRS prolon‑
gation, PVC, Ventricular Tachycardia, 
Atrial fibrillation, Atrial flutter
 +  + No data
Myotonic dystrophy type 2 Up to 25 DCM, HCM Atrial fibrillation  + / +  +  + 
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Due to individual predispositions, even mild initial dys-
function may lead to severe heart failure over months to 
years [14, 15]. However, systematic follow-up analysis in 
patients with MD2 and FSHD1 are lacking. Table 1 pro-
vides an overview of the most common muscular dystro-
phies and their associated cardiac abnormalities.
The aim of this study was to investigate a potential pro-
gression of the cardiac remodeling processes, including 
focal myocardial injury and function, in patients with 
MD2 and FSHD1 by applying serial CMR. Furthermore, 
we evaluated its relation to arrhythmias and conduction 
abnormalities.
Methods
Follow-up was performed in 83 patients with genetically 
confirmed diagnosis of MD2 and FSHD1 who had previ-
ously participated in our studies [12, 13].
A detailed medical history was recorded including 
symptoms related to cardiovascular diseases, medica-
tion and cardiovascular risk factors. Known myocardial 
infarction or myocarditis were considered as exclusion 
criterion to avoid an overlap with myocardial injury due 
to a different cause. Blood pressure was taken before and 
after CMR. Assessment of heart rhythm abnormalities 
was based on a 12-lead electrocardiogram (ECG) and 
on 24 h ECG-monitoring. Patients were also considered 
at risk of SCD according to the Groh-criteria: no sinus 
rhythm, PR interval ≥ 240  ms, QRS duration ≥ 120  ms, 
second- or third-degree atrioventricular block [16].
Significant arrhythmias were defined as frequent pre-
mature ventricular contractions (PVC ≥ 1000 /24-h), epi-
sodes of non-sustained ventricular tachycardia (NSVT), 
runs of supraventricular tachycardia (SVT) and 2nd/3rd 
degree atrioventricular (AV) block.
The local university ethical board approved the study 




CMR was performed on a 1.5 T scanner (MAGNETOM 
AvantoFit®, Siemens Healthineers, Erlangen, Germany) 
using a 32-channel surface coil.
Cine imaging was performed applying a balanced 
steady state free precession (bSSFP) sequence to deter-
mine the global cardiac performance. We acquired the 
following long axis views for the LV: four chamber (4Ch), 
three chamber (3Ch) and two chamber (2Ch) views 
and for the right ventricle (RV) a single long axis view 
(echo time (TE) 1.2  ms; repetition time, 33  ms; voxel 
size 1.8 × 1.8 × 6.0   mm3) as well as a short axis (SAx) 
package (TE 1.2  ms; repetition time, 63  ms; voxel size 
1.4 × 1.4 × 7.0  mm3) to cover the LV.
For myocardial tissue differentiation parametric T1- 
and T2-mapping, fat/water-separated imaging and focal 
fibrosis imaging (late gadolinium enhancement, LGE) 
were acquired. An overview of the scan protocol is pro-
vided in Fig. 1.
A multi-echo sequence was used for fat/water-separa-
tion [17] in 4ch view and five SAx slices (gradient echo 
sequence (GRE), double inversion recovery dark blood 
preparation, four echoes with monopolar readout, TR 
824 ms, TE 1.6–3.9–6.2–8.6 ms, slice thickness 6 mm).
We used the same contrast agent as in the previous 
studies (0.2  mmol/kg body weight of  gadoteridol for 
MD2 and 0.15  mmol/kg body weight of  gadobutrol for 
FSHD1). [12, 13].
LGE was performed in the same slice position as cine 
imaging in 4Ch, 3Ch, 2Ch views and SAx orientations 
Fig. 1 Scan protocol
Page 4 of 16Blaszczyk et al. J Cardiovasc Magn Reson          (2021) 23:130 
(gradient echo sequence, breath-held segmented pro-
tocol with 10  ms echo spacing, TE of 5.2  ms, and slice 
thickness of 7  mm) 10–15  min after administration of 
contrast agent.
T2- and T1-mapping were performed in basal, mid 
and apical slices as described [12, 18]. Calculations were 
carried out for each segment and for each slice. Motion-
corrected T2 mapping was based on a fast low angle shot 
(FLASH) gradient echo sequence in 4ch and SAx views 
as basal, mid-ventricular and apical slices. T2 maps 
were based on images with T2 preparation at times of 
0/30/55 ms, and slice thickness of 6.0 mm, TR 251.49 ms 
and TE 1.32 ms.
Motion-corrected T1 mapping based on Modified 
Look-Locker Inversion Recovery (MOLLI) technique 
was performed before and 15  min after contrast media 
application using for T1 native: 5  s(3  s)3  s and for T1 
post-contrast: 4 s(1 s)3 s(1 s)2 s pattern in 4Ch view and 
three SAx views with basal, mid-ventricular and apical 
slices (imaging parameters: TR = 281.64  ms (4ch) and 
332.67 ms (SAX), TE = 1.12 ms, slice thickness 6.0 mm, 
GRAPPA acceleration factor 2).
Data analysis
In the first paper (2016) we used cvi42 (version 4.1.2, Cir-
cle Cardiovascular Imaging, Calgary, Alberta, Canada). 
The analysis of the MD2 cohort at follow-up was per-
formed in 2018/2019. At that timepoint, we switched 
to cvi42 (version 5.3.2, Circle Cardiovascular Imaging). 
Because of potential influences and possible inconsisten-
cies between different software versions, a quality assur-
ance test was performed (re-evaluation of the baseline 
results with the new version in a randomly chosen sub-
group). There were no significant differences between 
the quantitative results. For the FSHD1 group we used 
the same version of Circle software (version 5.3.2, Circle 
Cardiovascular Imaging) for both baseline and follow up 
evaluations.
SAx cine images were used to determine LVEF and 
right ventricular (RV) ejection fraction (RVEF), volumes 
and LV mass by drawing endo- and epicardial contours 
(papillary muscles as part of the mass) at the end of the 
systolic and diastolic phases [19].
We quantified the left atrium (LA) area based on the 
biplanar approach using 2- and 4ch. For right atrium 
(RA) quantification 4Ch view cine images in LV systole 
were used. Furthermore, LA volume and ejection frac-
tion were quantified based on the biplanar approach [20].
The quantitative analysis of mapping was performed as 
average value for slice as well as for each segment. The 
region-of-interest ROI was defined by the delineation 
of the endocardial and epicardial border of the myocar-
dium. To ensure that blood or extra myocardial tissue 
were not included, endo- and epicardial offset of 5% was 
used. The segments were defined following the American 
Heart Association (AHA) segment model. The qualitative 
survey implied the exclusion of segments in case of arti-
facts (e.g., caused by susceptibility effects or unintended 
thoracic motion) or wrong motion correction.
The visual evaluation of the LGE images was performed 
by two independent, experienced readers (SCMR Level 
III) to assess presence, number and location of focal 
scars.
Quantification of LGE was performed with the estab-
lished semi-automated signal threshold versus reference 
mean (STRM) method [21]. On all LGE images, endo-
cardial and epicardial contours were manually traced 
and ROIs were defined in hyperenhanced and remote 
myocardium.
LGE was defined as myocardial signal intensity plus 3 
standard deviations (SD) above remote, normal-appear-
ing myocardium. The automated LGE detection could be 
manually corrected by the reader for a specific location 
to exclude obvious artifacts. After segmentation, myocar-
dial and scar tissue (in %) were calculated [21, 22].
Fibrosis volume and the total cell volume were derived 
using extracellular volume fraction (ECV) and the follow-
ing formulas [23]:
Fat/water-separation imaging was analyzed using pre-
defined criteria. A suspected region was considered posi-
tive if the intramyocardial fat was detectable (a) in the 
fat-separated image (hyperintense) and in the water-sep-
arated image (hypointense) or (b) detected in one of the 
separated images as well as in the cine imaging and LGE. 
Within the LV segmental analysis was performed follow-
ing the AHA segment model [24].
Global longitudinal strain (GLS) using CMR fea-
ture tracking was assessed from the 4Ch, 3Ch, and 2Ch 
images. Endo- and epicardial contours were manu-
ally drawn in end-diastolic phase, defined as the phase 
with the largest LV volume. Trabeculae, papillary mus-
cles, pericardium, and epicardial fat were consequently 
excluded from contouring [25].
Statistical analysis
The statistical analysis was performed using SPSS® 
(version 25, Statistical Package for the Social Sciences, 
International Business Machines, Inc., Armonk, New 
Fibrosis volume = ECV ∗ LVmass/myocardial density∗
Cell volume = ((1 − ECV ) ∗ LV mass)∕myocardial density ∗
∗myocardial density = 1.05 g/m.
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York, USA). All results are shown as mean ± standard 
deviation. Normal distribution was analyzed graphi-
cally using the Kolmogorov–Smirnov test. For com-
paring FSHD1/MD2 patients before and after the 
follow-up period we used the Mann–Whitney-U test. A 
p value < 0.05 was considered to indicate a statistically 
significant difference. Intra- and inter-observer repro-
ducibility was analyzed using intra-class correlation 
coefficient (ICC) and 95% confidence interval (CI). ICC 
was classified as poor (ICC < 0.4), good (ICC = 0.4–
0.75) or excellent (ICC > 0.75). Images were analyzed 
twice by blinded readers.
Results
CMR analysis in MD2 and FSHD1 patients
Follow-up was available for 27 of 31 MD2 (87%) 
patients (follow up 3.9 ± 0.3  years) and 41 of 52 (80%) 
FSHD1 patients (follow up 2.0 ± 0.1 years). Six patients 
refused follow-up  CMR. Twenty-two patients with 
MD2 and 40 subjects  with FSHD1 underwent CMR 
with contrast. Baseline characteristics of patients at fol-
low-up are shown in Tables 2 and 3. Some patients dur-
ing the observation period received medications that 
could reduce the progression of cardiac remodeling and 
fibrotic processes: 10/22 MD2 and 7/41 FSHD1 patients 
received angiotensin converting enzyme (ACE) inhibi-
tors or angiotensin receptor blockers (ARBs), only 3 
patients in both groups received ß-blockers.
Myotonic dystrophy type II
Individual and mean changes between both baseline and 
follow-up groups are displayed in Fig. 2.
Remodeling
Left ventricular and right ventricular chamber anatomy
LVEF stayed within normal range, however was statisti-
cally lower at follow up  (LVEFbaseline 68 ± 6% vs  LVEFFU 
62 ± 6%, p = 0.001). After a mean observational period 
of four years, MD2 patients presented with significantly 
lower and mildly impaired RVEF compared to their 
baseline examinations  (RVEFbaseline 59 ± 7 vs  RVEFFU 
54 ± 4%, p = 0.001). Both ventricles showed no significant 
changes in volume during the course of time (LV end-
diastolic volume (LVEDV) p = 0.605 and indexed LVEDV 
(LVEDVI) p = 0.275, RVEDV p = 0.444 and RVEDVI 
p = 0.456.) (Table 4).
At follow up patients with focal fibrosis showed sig-
nificantly lower LVEF  (LVEFLGE+ 59 ± 2% vs  LVEFLGE- 
64 ± 4%, p = 0.005), however it still remained in normal 
ranges. LVEDV and LVEDVI did not change at follow 
up  (LVEDVLGE+ 142 ± 38 vs  LVEDVLGE- 119 ± 25  ml 
p = 0.127,  LVEDVILGE+ 0.81 ± 0.19 ml/m2 vs  LVEDVILGE- 
0.70 ± 0.13, p = 207).
Left atria and right atria quantification
We observed significant increase of the LA and RA areas 
(LA baseline 21 ± 3 vs LA FU 24 ± 5  cm2, p = 0.014, RA 
Table 2 Characteristics of patients with muscular dystrophy II 
(MD2) at follow‑up
Data are shown as mean values ± standard deviation (SD) according to the AHA-
segment model.   BP blood pressure
Presence of Late Gadolinium 
Enhancement
All (n = 22) No (n = 17) Yes (n = 5)
Age (years) 58 ± 9 57 ± 9 61 ± 10
Male sex, n (%) 6 (27.3) 4 2
Heart rate (beats per minute) 69 ± 9 68 ± 9 72 ± 11
Systolic BP (mmHg) 130 ± 16 127 ± 16 139 ± 16
Diastolic BP (mmHg) 75 ± 10 73 ± 10 81 ± 9
Arterial hypertension, n (%) 7 (31.8) 4 3
Hyperlipidemia, n (%) 16 (72.7) 13 3
Diabetes mellitus, n (%) 3 (13.6) 3 –
Smoking, n (%) 2 (9.1) 1 1
Cardiac symptoms
 Asymptomatic, n (%) 16 (72.7) 11 2
 Palpitations, n (%) 6 (27.3) 4 2
 Chest pain, n (%) 1(4.5) 1 0
 Fatigue, n (%) 5 (22.7) 4 1
Table 3 Characteristics of patients with Facioscapulohumeral 
muscular dystrophy type 1 (FSHD1) at follow‑up
Data are shown as mean values ± standard deviation (SD) according to the AHA-
segment model.   BP blood pressure
Presence of Late Gadolinium 
Enhancement
All (n = 40) No (n = 26) Yes (n = 14)
Age (years) 49 ± 14 47 ± 14 54 ± 11
Male sex, n (%) 29 (70.7) 9 (36) 3 (21.4)
Heart rate (beats per minute) 74 ± 13 76 ± 13 71 ± 14
Systolic BP (mmHg) 129 ± 15 127 ± 16 132 ± 15
Diastolic BP (mmHg) 79 ± 10 79 ± 9 79 ± 11
Arterial hypertension, n (%) 8 (20) 1 7
Hyperlipidemia, n (%) 7 (17.5) 3 4
Diabetes mellitus, n (%) 3 (7.5) 1 2
Smoking, n (%) 5 (12.5) 3 2
Cardiac symptoms
 Asymptomatic, n (%) 29 (70.7) 19 10
 Palpitations, n (%) 8 (12.2) 6 2
 Chest pain, n (%) 1(2.4) 1 0
 Fatigue, n (%) 6 (14.6) 4 2
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baseline 21 ± 3 vs RA FU 24 ± 5  cm2, p = 0.040), however 
LA volume showed no significant changes (for LAEDV 
p = 0.275 and for LAEDVI p = 0.288) (Table 4).
We observed an excellent intra- and inter-observer 
reproducibility for ventricular and atrial assessment in 
both groups. ICC was 0.091 for intra-observer and 0.892 
for inter-observer analysis.
Myocardial tissue differentiation
Parametric mapping, cell and fibrosis volume
We performed T2 and T1 mapping at baseline and dur-
ing follow-up. Native T1 values remained stable (MD2: 
basal p = 0.066, mid p = 0.258, apical p = 0.163), but ECV 
dropped significantly (MD2: basal p = 0.014, mid p < 0.01, 
apical p < 0.01). T2 decreased significantly as well (MD2: 
basal p < 0.01, mid p < 0.01, apical p < 0.01).
While the cell volume remained constant, patients at 
follow-up presented with lower fibrosis volume (MD2 
cell volume basal p = 0.409, mid p = 0.553; fibrosis vol-
ume basal p = 0.055, mid p = 0.009) (Table 4).
Focal fibrosis and its relation to cardiac remodeling
In the MD2 group, new focal fibrosis could be identi-
fied in 1 of 22 patients, (5%, female) at follow up. It was 
located in the basal segments of the inferolateral and 
inferoseptal wall. At follow-up, an increase of focal fibro-
sis was observed. In total 6/22 (27%,3 women) MD2 
patients had focal fibrosis (see Fig. 3 and Table 5).
Focal fat
New focal fat infiltration was observed in 2 of 22 patients 
(10%, both females), mostly located in the apical part of 
the interventricular septal wall (Fig. 4). Overall, fat infil-
tration was present in 7/22 (32%, all females) patients at 
follow-up.
Myocardial deformation‑ global longitudinal strain (GLS)
GLS was significantly lower in MD2 patients at follow in 
comparison to baseline  (GLSMD2 LGE (-) baseline -17.9 ± 1.0% 
vs.  GLSMD2 LGE (-) at follow up -16.8 ± 4.0%, p < 0.01). LGE ( +) 
patients were excluded to avoid the influence of known 
focal fibrosis.
Heart rhythm abnormalities and its relation to myocardial 
tissue changes
12-lead ECG was available in all patients, Holter-ECG in 
24/27 patients.
New arrhythmic events or conduction abnormalities 
were recorded in 10/27 patients (37%). New episodes of 
SVT occurred in 7 patients while a new AV block type 2 
Fig. 2 Changes of atria and ventricle parameters between baseline and follup in muscular dystrophy II (MD2) patients. Continuous lines are 
showing average values for: patients with focal fibrosis (red line), patients without focal fibrosis (grey line) and average value of all patients (green 
line) at baseline and follow‑up. Dashed lines are presenting the values for each individual: with focal fibrosis (red line) and patients without focal 
fibrosis (grey line)
Page 7 of 16Blaszczyk et al. J Cardiovasc Magn Reson          (2021) 23:130  
was detected in only 1 patient. Two patients displayed new 
conduction abnormalities, specifically right bundle branch 
block and left anterior hemiblock. Positive Groh-criteria 
(AV block type 1) could be identified in only one patient. 
Arrhythmias or conduction disturbances were observed in 
all seven patients with fatty infiltrations and 4 of 6 patients 
with focal fibrosis. See Table 5.
Facioscapulohumeral Muscular Dystrophy 1 
(FSHD1)
Individual and mean changes between baseline and fol-
low-up in both groups are displayed in Fig. 5.
Remodeling
Left ventricular and right ventricular chamber size 
and function
During the follow up period, LVEF remained within the 
normal range  (LVEFbaseline 63 ± 5% vs  LVEFFU 60 ± 3%, 
p = 0.762). There was no significant progression of RV 
dysfunction, however RVEF in FSHD1 patients was 
mildly impaired  (RVEFbaseline 51 ± 6 vs  RVEFFU 49 ± 5%, 
p = 0.001). Volume in both ventricles stayed within nor-
mal range during the course of time, however LVEDVI 
increased significantly at follow-up (LVEDV p = 0.131 
Table 4 CMR parameters of patients with MD2 and FSHD1 at baseline and at follow‑up
Data are shown as mean values ± standard deviation (SD) according to the AHA-segment model. Significant differences (p < 0.05) are highlighted in bold
BMI body mass index, BSA body surface area (Mosteller), HR heart rate, BP blood pressure, LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic 
volume, LVEDVI eft ventricular end-diastolic volume index, LVESV left ventricular end-systolic volume, LA    left atrium, RA right atrium, GLS global longitudinal strain, 
ECV extracellular volume fraction
Parameter MD2 FSHD1
Baseline (n = 31) Follow-up n = 22 p-value Baseline n = 52 Follow-up
n = 41
p value
LVEF (%) 68 ± 6 62 ± 6  < 0.01 63 ± 5 60 ± 3 0.762
LVEDV (ml) 126 ± 22 124 ± 29 0.605 128 ± 21 139 ± 34 0.131
LVEDVI (ml/cm) 0.80 ± 0.11 0.73 ± 0.15 0.275 0.70 ± 0.10 0.79 ± 0.17  < 0.01
LV mass (g) 104 ± 27 92 ± 24 0.124 99 ± 25 102 ± 24 0.630
LV mass index (g/cm) 0.60 ± 0.14 0.54 ± 0.12 0.110 0.56 ± 0.13 0.57 ± 0.12 0.524
LV stroke volume (ml) 85 ± 13 78 ± 17 0.113 80 ± 15 84 ± 18 0.084
LV stroke volume index (ml/m2) 46 ± 6 42 ± 6 0.063 45 ± 8 48 ± 9 0.245
RVEF (%) 59 ± 7 54 ± 4  < 0.01 51 ± 6 49 ± 5 0.104
RVEDV (ml) 140 ± 29 146 ± 33 0.444 160 ± 31 169 ± 28 0.470
RVEDVI (ml/m2) 76 ± 15 79 ± 14 0.456 83 ± 16 88 ± 14 0.422
RV stroke volume (ml) 82 ± 18 80 ± 19 0.932 76 ± 18 83 ± 18 0.082
RV stroke volume index (ml/m2) 44 ± 89 43 ± 8 0.852 40 ± 8 43 ± 8 0.063
LAEF (%) 60 ± 8 57 ± 7 0.392 62 ± 8 60 ± 7 0.452
LAEDV (ml) 63 ± 18 71 ± 25 0.275 54 ± 14 61 ± 14 0.021
LAEDVI(ml/m2) 35 ± 8 38 ± 25 0.288 28 ± 7 32 ± 8 0.027
LA (cm2) 21 ± 3 24 ± 5  < 0.01 19 ± 3 22 ± 3  < 0.01
RA (cm2) 21 ± 3 24 ± 5 0.040 20 ± 3 23 ± 4 0.029
Native T1 basal (ms) 1029 ± 30 1015 ± 38 p = 0.066 1010 ± 26 991 ± 24  < 0.01
Native T1 mid (ms) 1012 ± 38 998 ± 30 p = 0.258 991 ± 39 989 ± 30 p = 0.102
Native T1 apical (ms) 1018 ± 50 999 ± 32 p = 0.163 983 ± 41 970 ± 40 p = 0.203
ECV basal (%) 26 ± 3 24 ± 3  < 0.01 26 ± 3 22 ± 2  < 0.01
ECV mid (%) 26 ± 2 24 ± 2  < 0.01 26 ± 3 23 ± 3  < 0.01
ECV apical (%) 29 ± 3 26 ± 2  < 0.01 27 ± 3 24 ± 2  < 0.01
T2 basal (ms) 51 ± 2 49 ± 2  < 0.01 50 ± 4 47 ± 2  < 0.01
T2 mid (ms) 52 ± 3 49 ± 3  < 0.01 51 ± 3 47 ± 2  < 0.01
T2 apical (ms) 55 ± 4 50 ± 2  < 0.01 53 ± 3 48 ± 2  < 0.01
Cell volume basal (ml) 72 ± 18 68 ± 17 p = 0.409 71 ± 19 74 ± 22 p = 0.308
Cell volume mid (ml) 70 ± 19 76 ± 17 p = 0.553 71 ± 20 73 ± 22 p = 0.361
Fibrosis volume basal (ml) 25 ± 9 20 ± 7 p = 0.055 24 ± 8 20 ± 7 p = 0.023
Fibrosis volume mid (ml) 26 ± 7 21 ± 6  < 0.01 23 ± 7 22 ± 7 p = 0.032
GLS (%) LGE(-) patients ‑17.9 ± 1 ‑16.8 ± 1  < 0.01 ‑18.3 ± 1 ‑16.4 ± 1 p < 0.01
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and LVEDVI p = 0.013, RVEDV p = 0.470 and RVEDV-I 
p = 0.422; Table 4).
Quantification of the left atria and right atria size
We observed a significant progression of both LA and RA 
areas (LA baseline 19 ± 3 vs LA FU 22 ± 3  cm2, p < 0.001, RA 
baseline 20 ± 3 vs RA FU 23 ± 4  cm2, p = 0.029) as well as LA 
volume (for LAEDV p = 0.271 and for LAEDVI p = 0.227).
Myocardial tissue differentiation
Parametric mapping, cell and fibrosis volume
We performed T2 and T1 mapping at baseline and dur-
ing follow-up. Native T1 values dropped in basal slices 
but remained stable in mid and apical slices (FSHD1: 
basal p = 0.001, mid p = 0.102, apical p = 0.203). ECV 
dropped significantly within three whole slices (basal 
p < 0.001, mid p < 0.001, apical p < 0.001). T2 mapping val-
ues decreased significantly similarly as in MD2 patients 
(basal p < 0.001, mid p < 0.001, apical p < 0.001). Interest-
ingly, we observed the same phenomenon to that in MD2 
patients regarding the cell and fibrosis volume. While the 
cell volume remained constant, patients at follow-up pre-
sented a statistically lower volume of fibrosis (cell volume 
p = 0.306, mid p = 0.361, fibrosis volume basal p = 0.023, 
mid p = 0.032). We included detailed information in the 
table with the CMR parameters (Table 4).
Focal fibrosis and its relation to cardiac remodeling
In the FSHD1 group, new focal fibrosis was detected in 
2 of 40 patients (6%, male). The fibrosis was located infe-
rolateral and inferoseptal. Overall, in 15 of 40 (37%, 3 
females) patients focal fibrosis could be identified. The 
pattern of the fibrosis was non-ischemic with an intra-
mural and subepicardial distribution (Fig. 6). During the 
follow-up we also observed a quantitative increase in 
focal fibrosis (Table 5).
At follow up, patients with focal fibrosis showed no sig-
nificant changes in LVEF  (LVEFLGE+ 60 ± 7% vs  LVEFLGE- 
60 ± 6%, p = 0.356), as well as in LVEDV and LVEDVI 
 (LVEDVLGE+ 152 ± 46 vs  LVEDVLGE- 132 ± 23  ml 
p = 0.242,  LVEDVILGE+ 0.86 ± 0.23 ml/m2 vs  LVEDVILGE- 
0.74 ± 0.10, p = 131).
Focal fat
New focal fat infiltration was observed in 5 of 40 
patients (13%, 1 female). Majority was located in the 
apical part of the interventricular septal wall. In one 
patient the infiltration was found in the inferior wall 
(Fig. 7). Intramyocardial fat could be detected in 12 of 
40 patients (30%, 3 female).
Myocardial deformation‑ global longitudinal strain (GLS)
To avoid the influence of known focal fibrosis, after 
exclusion of LGE ( +) patients, GLS was significantly 
lower in FSHD1 patients at follow in comparison to 
Fig. 3 MD2 patient with progressive intramyocardial fibrosis and conduction abnormalities (atria‑ventricular (AV) Block I, left anterior hemiblock) 
and still preserved ejection fraction. 1A–1D at baseline. 2A–2D at follow‑up. Cine images in 4ch in diastole (1, 2 A) and systole (1,2 B). Late 
gadolinium enhancement (LGE) in short axis views (1, 2 C, D)
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Table 5 Clinical characteristics and imaging findings according to the distribution of late gadolinium enhancement (LGE) and fat 
infiltration in DM2 and FSHD1 patients at baseline and at follow‑up
SVT = supraventricular tachycardia, VT = ventricular tachycardia, PVC = premature ventricular contractions, LBBB = left bundle branch block, RBBB = right bundle 
branch block, LAH = left anterior hemiblock, LGE = late gadolinium enhancement. ACE-I = angiotensin-converting enzyme (ACE) inhibitors, ARBs = angiotensin II 
receptor blockers
All DM2 patients DM2 LGE (+) DM2 Fat (+)




Baseline n = 6 Follow-up 
n = 7
SVT (n) 2 9 – 5 – 5
Non‑sustained VT n (n) – – – – – –
Frequent PVC (≥1000/24h) (n) – – – – – –
AV Block I (n) 4 5 2 2 2 2
AV Block II (n) – 1 – – – –
LBBB 1 1 1 1 1 1
RBBB 1 2 – 1 – –
LAH 2 3 – 1 – –
LGE location and global volume 5 6
Inferolateral basal (n)) 5 6 5 6 1 3
Anterolateral basal (n) – 2 – 2 – –
Septal (n) 1 1 1 1 – –
LGE area ‑ mean (%) 8.4 17.6
Fat apical 6 7
Medical therapy
Beta blockers (n) 1 3 – 1 – 1
ACE, Sartans (n) 4 10 1 2 – 2
All FSHD1 patients FSHD1 LGE (+) FSHD1 Fat (+)
Type of 
Arrhythmias
Baseline (n = 52) Follow-up (n = 40) Baseline (n = 13) Follow-up (n = 15) Baseline (n = 7) Follow-up 
(n = 12)
SVT (n) 1 8 1 3 – 5
Non‑sustained VT 
n (n)
1 2 1 2 1 1
Frequent PVC 
(≥1000/24h) (n)
2 11 1 8 2 3
AV Block I (n) 1 3 1 1 – 1
AV Block II (n) – – – – – –
LBBB – – – – – –
RBBB – – – – – –
LAH – – – – – –
LGE location and 
global volume
13 15 2 3
Inferolateral basal 
(n))
7 7 7 7 – –
Anterolateral basal 
(n)
2 1 2 1 – –
Septal (n) 3 3 3 3 – –
Inferior (n) 1 3 1 3 – –
LGE area ‑ mean (%) 18.6 28.9
Fat apical 7 12
Medical therapy
Beta blockers (n) 1 4 1 1 3
ACE‑I, ARBs (n) 2 7 1 3 1 2
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baseline  (GLSFSHD1 LGE (-) baseline -18.3 ± 1% vs.  GLSFSHD1 
LGE (-) at follow up -16.4 ± 1%, p < 0.01).
Heart rhythm abnormalities and its relation to myocardial 
tissue changes
12-lead ECG was available in all patients, Holter-ECG 
in 34 of 40 patients (85%) with the diagnosis of FSHD1. 
The lack of data was due to patient related reasons.
New arrhythmic events were recorded in 10 of 34 
patients (29%). NSVT was detected in one patient, 
runs of SVT in eight patients. Groh-criteria could not 
be identified. Holter was not available in 5/34 patients 
with focal fibrosis and/or fat infiltration. Ventricular 
arrhythmias (PVC > 1000) were observed in 8 patients 
with focal fibrosis and 3 patients with fat infiltration. 
SVTs were present in 5 patients with fatty infiltrations 
and 3 patients with focal fibrosis (Table 5).
Discussion
In this  study, we demonstrate that cardiac remodeling 
is progressive in both MD2 and FSHD1. Even in the 
absence of significant cardiac symptoms we observed 
a progression of structural and functional changes 
regarding all cardiac chambers.
The incidence of myocardial tissue changes such 
as focal fibrosis and fat infiltration was also higher at 
follow-up. There seems to be a relationship between 
structural abnormalities and abnormal heart rhythms 
and conduction abnormalities/disturbances. To the 
best of our knowledge, this is the first follow-up study 
applying CMR in patients with MD2 and FSHD1.
In inherited neuromuscular disorders such as DMD 
and BMD the development of a cardiomyopathy and/or 
heart failure is the second most important cause of death 
after respiratory failure. LV focal fibrosis was described 
in approximately 70% of these patients [26, 27]. The 
Fig. 4. 4‑chamber view. Patient with MD2 and new apical fat infiltration. CMR 1: fat‑separated image (1a) and water‑separated image (1b) without 
evidence of fat infiltration. CMR 2: new apical fat infiltration, bright in the fat‑separated image (2a) and hypointense (2b) in the water‑separated 
image
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progression of myocardial fibrosis in other forms of MD 
are already well known [27, 28]. Furthermore, follow-up 
studies performed in DMD carriers showed progressive 
myocardial changes such as focal fibrosis and impaired 
LVEF [29]. In our study, we found that almost 30% of 
patients with MD2 and FSHD1 had focal fibrosis despite 
a preserved LVEF. However, in FSHD1 patients RVEF 
was mildly impaired starting already at baseline. During 
follow-up the remodeling of ventricle and atria was pro-
gressive. LV and RV functions worsened in both patient 
groups. Furthermore, we observed an increase of atrial 
size which was more evident in patients with known 
supraventricular arrhythmias. In almost 26% of patients 
with MD2, diabetes mellitus was already present at base-
line. With this being a traditional cardiovascular risk fac-
tor associated with vascular events, it could contribute to 
cardiac remodeling, nevertheless all patients with focal 
fibrosis showed a non-ischemic LGE pattern.
Myocardial fat infiltration is a less studied matter in 
comparison to focal fibrosis as detection of fat by apply-
ing CMR is challenging. Thanks to recent technical devel-
opments identification of even small changes is feasible 
[17]. A correlation between fatty infiltration and arrhyth-
mia frequency is already known in different diseases. Lu 
et  al. reported the presence of myocardial fat in dilated 
cardiomyopathy (DCM) patients and its significant 
relationship to LV global function as well as a possible 
influence on the prognosis of DCM [30]. However, larger 
data sets are still missing and fatty remodeling seems 
to be underestimated and understudied. Fat within api-
cal septum was reported also in healthy, however in our 
study focal fat infiltration was present in a much higher 
percentage of the studied cohort (30% of MD2 and 
FSHD1 patients). Especially in our MD2 patient group, 
all arrhythmic events were associated with the presence 
of fatty infiltrations, possibly underlying the impact on 
conduction abnormalities as discussed below.
In most patients with MD the LV is affected, presenting 
with a dilatation or reduced LVEF. However, over a span 
of the last few years there has been increasing awareness 
of the potential impact of RV impairment. RV and atrial 
remodeling may also dominate with clinical manifesta-
tions in neuromuscular diseases. These findings are often 
combined with rhythm- and conduction abnormalities 
[31]. Cardiac conduction abnormalities and atrial tach-
yarrhythmias are commonly observed in inherited MD 
and may also evolve from myocardial remodeling [32]. In 
patients with myotonic dystrophy type 1 (MD1), rhythm 
and conduction abnormalities are the dominant features 
of cardiac involvement, while heart failure seems to not 
be the most frequent finding in this entity. Asympto-
matic MD1 patients with Groh-criteria were at higher 
Fig. 5 Changes of atria and ventricle parameters between baseline and at follow up in FSHD1 patients. Continuous lines are showing average 
values for: patients with focal fibrosis (red line), patients without focal fibrosis (grey line) and average value of all patients (green line) at baseline and 
follow up. Dashed lines are presenting the values for each individual: with focal fibrosis (red line) and patients without focal fibrosis (grey line)
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Fig. 6. 34‑year‑old asymptomatic man with FSHD1 presenting short episode of non‑sustained ventricular tachycardia (VT) in Holter‑ECG (4D) and 
evidence on LGE‑CMR (LGE in 4Ch 4A and short axis 4B) involving LV lateral wall. Extracellular volume fraction (ECV) map in 4ch 4C 
Fig. 7. 2‑chamber view. Patient with FSHD1 and new intramyocardial apical fat infiltration‑ white circles. Bright in the fat‑separated image (left) and 
hypointense (right) in the water‑separated image. Epicardial fat – white arrows
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risk of SCD when compared to those with normal ECGs. 
In Emery Dreifuss MD cardiac involvement is predomi-
nantly identified by conduction defects and atrial fibril-
lation/flutter. These patients often show atrial dilation in 
different stages [32, 33].
Patients with MD2 and FSHD1 are known to suffer 
from supraventricular arrhythmias as well as conduc-
tion disturbances like AV blocks [11]. In our group we 
observed the progression of atrial enlargement and a 
decrease of atrial function. This may explain the progres-
sion of SVT. Recently published studies have shown that 
multiple atrial premature contractions and SVTs predict 
stroke recurrence in patients with cryptogenic stroke 
without atrial fibrillation and may be a reproducible 
marker of atrial myopathy [33, 34]. Interestingly, Winter-
holler et al. showed an increased risk for ischemic strokes 
in DMD patients. It is suspected that cardioembolic 
stroke is an under-recognized complication in patients 
with MD [34–36].
Parametric mapping is a method that brings unique 
quantitative diagnostic information concerning the 
myocardium.
In our cohorts we observed an increase of the number 
of focal myocardial changes as well as a worsening of 
GLS. T2 decreased significantly. T1 values stayed sta-
ble in most segments while ECV dropped significantly 
in both groups. The correlation of the EVC to the LV-
morphology showed, that meanwhile the cell volume 
stayed constant, the volume of fibrosis was lower at 
follow-up. The cause for the decrease remains specula-
tive (possible cardioprotective medication, progressive 
fat infiltration?). We have further discussed progressive 
fat infiltration as a possible explanation, as one could 
expect especially in this disease, further remodeling 
in this direction. However, we refused this possibil-
ity because T2 decreased. The explanation remains 
speculative, but an influence of anti-remodeling medi-
cations and myocardial deoxygenation could explain 
the observed mapping variations. We assume, that the 
decrease of T2 can be explained by T2* effects and may 
reflect a deterioration of myocardial oxygenation that 
may play a role in the further development of fibrosis. 
It was previously shown, that lower T2* mapping values 
are related to alterations in the myocardial microcir-
culation. Manka et al. showed that BOLD CMR (blood 
oxygen level dependent) at rest revealed significantly 
lower T2* values for segments supplied by > 50% sten-
osed vessels [37]. Friedrich et al. presented the decrease 
of signal intensity during adenosine perfusion imag-
ing within segments related to coronary artery sten-
oses > 75% [38]. Significant changes were also found 
in hypertensive patients compared to healthy controls 
[39].
We assume that the decrease of ECV at follow-up is 
probably related to a change of therapy between the two 
time points. The cardioprotective medication was opti-
mized including ACE inhibitors. This may play a role 
in regards to the myocardial tissue changes within the 
whole group. Interestingly, Raman et  al. could further 
show, that ACEI and mineralocorticoid receptor antag-
onists have an influence on fibrosis in MD [40]. There 
is no systematic CMR analysis investigating the effects 
of beta receptor blockade. This thesis is supported by 
our calculations, which show a reduced fibrosis volume 
with an unchanged total cell volume. Further follow-up 
trials will help to increase the understanding of these 
phenomenon’s and to define its impact on the patient 
prognosis.
Quantification of myocardial deformation is of grow-
ing interest in CMR. Although relatively new, CMR fea-
ture tracking has been performed in various myocardial 
diseases like cardiomyopathies, aortic valve diseases or 
myocardial infarction. It allows quantification of global 
and regional myocardial deformation offering addi-
tional information beyond ejection fraction and has 
the potential to detect subclinical myocardial dysfunc-
tion in patients with non-ischemic heart disease even 
in preserved ejection fraction and without wall motion 
abnormalities [41, 42].
In our cohort, GLS was significantly lower at follow 
up although global LV function was preserved. That 
could also be shown in patients without focal myocar-
dial injury. It seems that a volumetric approach using 
LVEF may be less reliable during the first years of fol-
low-up regarding the early phase of subclinical LV 
remodeling.
In our study we observed a remarkably fast progres-
sive decline of the cardiac morphology and function as 
well as a progression of rhythm disturbances including 
arrhythmias, even in asymptomatic patients (see Fig. 5). 
Both ventricles as well as atria were affected. The changes 
occurred within 2–5  years. This underlines the need 
for routine ECG or echocardiographic testing even in 
asymptomatic patients. Currently, routine ECG and/or 
echocardiographic exams are only indicated in sympto-
matic FSHD1 patients.
Further multi-center follow-up studies are needed to 
understand the relation between cardiac remodeling in 
MD and the outcome. However, regular use of CMR for 
follow-up in these patients may provide a valuable risk 
stratification tool in the future.
Limitations
Our sample size is relatively small, but both cohorts 
are recognized as rare diseases and this is the first 
follow-up study in this cohort. It was not possible to 
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perform ECG-monitoring in all patients due to logisti-
cal reasons. This is an observational prospective cohort 
study, therefore there was no randomization into differ-
ent treatment groups. Nevertheless, there is a poten-
tial impact of many other factors like progressive fat 
infiltration as well as the received therapy during the 
follow-up period, which should be taken into consid-
eration. Currently, there are not enough data to report 
outcome analysis.
Conclusions
Patients with MDs gain an increasing awareness in 
cardiology. We observed a remarkably fast progressive 
decline of cardiac morphology and function as well as a 
progression of rhythm disturbances including arrhyth-
mias, even in asymptomatic patients. These changes 
occurred within a short period of time. It seems that a 
potential association between an increase of arrhyth-
mias and progression of myocardial tissue damage such 
as focal fibrosis and fat infiltration exists. Our data sug-
gest that these patients should be carefully followed to 
identify early development of remodeling and potential 
risks for the development of furthers cardiac events 
even in the absence of symptoms.
Longitudinal multi-center trials with a larger sample 
size will help to define the impact of our findings as 
well as further demonstrate a correlation between myo-
cardial injury and arrhythmias in regards to long-term 
prognosis and therapeutic decision-making.
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